GURU.Markets stock price, segment price, and overall market index valuation
The company's share price INDP
Indaptus is a biotech company developing cancer immunotherapy drugs. Its stock price represents a venture bet on its scientific platform. The chart reflects the high volatility associated with clinical trial news.
Share prices of companies in the market segment - Pharma immune
Indaptus Therapeutics is an oncology company developing immunotherapies that use weakened bacteria to activate both innate and adaptive immunity against cancer. We've categorized it under "Pharma: Immunology." The chart below shows the dynamics in this cutting-edge sector.
Broad Market Index - GURU.Markets
Indaptus Therapeutics is a biopharmaceutical company developing immunotherapy drugs for the treatment of cancer and viral infections. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
INDP - Daily change in the company's share price INDP
For Indaptus Therapeutics, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma immune
Indaptus Therapeutics is developing a universal immunotherapy for the treatment of cancer and infections using bacterial vectors. This is a cutting-edge and risky approach. The chart below illustrates the high volatility typical of immuno-oncology, providing context for INDP's valuation.
Daily change in the price of a broad market stock, index - GURU.Markets
Indaptus Therapeutics is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization INDP
For Indaptus Therapeutics, the year-over-year trend is a story about the development of its unique immunotherapeutic platform. Its 12-month market cap depends entirely on early clinical trial data. The success of its approach, which uses weakened bacteria to stimulate the immune system, could lead to a breakthrough in cancer treatment.
Annual dynamics of market capitalization of the market segment - Pharma immune
As an early-stage biotech, Indaptus is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its immunotherapy. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Indaptus Therapeutics is an immuno-oncology company whose stock is a bet on a new generation of cancer drugs. Its performance is completely disconnected from the market and is determined by news of the clinical successes or failures of its bacterial therapy. It's a high-risk play where scientific data is everything.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization INDP
Indaptus is an immuno-oncology company. Its monthly performance is driven by progress in its clinical trials. Positive data on its platform, presented at conferences, and partnership news are the main drivers of its valuation.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Immuno-oncology is the cutting edge of the fight against cancer. The dynamics of this biotech sector, shown in the chart, reflect investors' belief in the ability to activate a patient's own immune system. Companies like Indaptus Therapeutics are developing their platform in this area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Indaptus Therapeutics, a biopharmaceutical company working in the field of immunotherapy, lives in a world of clinical data. Its shares rise and fall on trial news, defying overall market trends. This chart demonstrates this independence.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization INDP
Shares of Indaptus Therapeutics, a company developing a novel cancer immunotherapy, are extremely volatile. Weekly price movements depend entirely on news about the progress of preclinical and clinical trials of their technology. The chart below illustrates how short-term scientific developments and investor expectations shape value in innovative oncology.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Indaptus Therapeutics is developing a new approach to cancer immunotherapy. The success or failure of a single clinical trial could determine the company's fate. The chart will show how much its weekly performance reflects the unique risks and hopes associated with its scientific platform, rather than general market trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Indaptus Therapeutics develops immunotherapy. This chart shows how its weekly performance, like that of other biotechs, is detached from the market. Its stock moves are driven by news about clinical trials and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
INDP - Market capitalization of the company INDP
Indaptus Therapeutics's market cap is a bet on its unique approach to activating the immune system to fight cancer. The company's clinical-stage valuation depends on whether its technology proves effective in humans. The chart illustrates the high risk and potential of this new field in immuno-oncology.
INDP - Share of the company's market capitalization INDP within the market segment - Pharma immune
Indaptus Therapeutics' market share in immuno-oncology reflects its unique approach to "awakening" the immune system to fight cancer. Its market share stems from its bacterial platform, which can make tumors "visible" to immune cells, opening new avenues for treatment.
Market capitalization of the market segment - Pharma immune
Here's a chart of the total market capitalization of biotech companies developing immunostimulant drugs. Indaptus Therapeutics is one of the innovators in this field. The graph shows how the market values technologies that can "wake up" the immune system to fight cancer and infections.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph visualizes the hope for a new way to "awaken" the immune system against cancer. Indaptus Therapeutics' market cap reflects the potential of its unique bacterial therapy. The line shows how this breakthrough scientific idea is competing for its share of the future of global immuno-oncology.
Book value capitalization of the company, segment and market as a whole
INDP - Book value capitalization of the company INDP
Indaptus Therapeutics' book value represents its scientific capital. The chart below reflects the valuation of its unique platform for activating the immune system to fight cancer and infections. The pipeline's growth reflects advances in preclinical and clinical research, which are the biotech company's core assets.
INDP - Share of the company's book capitalization INDP within the market segment - Pharma immune
For Indaptus Therapeutics, which is developing a new immunotherapy, its tangible assets are its laboratories and, potentially, manufacturing facilities. The chart reflects its stake in this scientific infrastructure, which provides the physical basis for activating the immune system to fight cancer and infections.
Market segment balance sheet capitalization - Pharma immune
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Indaptus Therapeutics, as a development company, has a more streamlined model. Its value lies in its unique scientific platform, not in the scale of its production.
Book value of all companies included in the broad market index - GURU.Markets
Indaptus Therapeutics is developing a new approach to cancer treatment using bacteria to activate the immune system. The company's assets include a unique biotech platform and manufacturing processes for these "living drugs." The chart below shows the financial weight behind this bold idea.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - INDP
Indaptus Therapeutics is an immuno-oncology company. Its market value is derived from its unique approach to activating the immune system against cancer and viral infections. This is a bet on its scientific platform, not its current assets.
Market to book capitalization ratio in a market segment - Pharma immune
Indaptus Therapeutics is a biotech company developing a platform for activating the immune system to fight cancer. Its value is based on the potential of this technology. This chart shows how its market valuation, reflecting its hopes for a breakthrough in immunotherapy, is a multiple of its current assets.
Market to book capitalization ratio for the market as a whole
Indaptus Therapeutics is a biotech company working to activate the immune system to fight cancer. This chart shows how the market values its unique scientific platform relative to its book value. Price fluctuations reflect expectations for preclinical and clinical studies.
Debts of the company, segment and market as a whole
INDP - Company debts INDP
Indaptus Therapeutics, an immuno-oncology company, is leveraging its financial structure to advance its unique anti-cancer and anti-viral platform. This chart shows how the company is funding its early clinical trials to prove the efficacy of its approach to activating the immune system.
Market segment debts - Pharma immune
Indaptus Therapeutics is a preclinical biotech company developing a novel platform for activating the immune system to fight cancer. This chart shows how its financial structure, virtually debt-free, reflects the very early stage of its development, which is funded exclusively by venture capital and equity.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio INDP
Conduit Pharmaceuticals operates under a unique model, acquiring and developing assets from large pharmaceutical companies. This chart shows how it uses capital to finance the acquisition and further development of these assets. The level of debt reflects its bet on the success of these "rescued" molecules.
Market segment debt to market segment book capitalization - Pharma immune
Indaptus Therapeutics is developing a new approach to immunotherapy for cancer and viral diseases, using bacterial vectors to activate the immune system. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the biotech company finances its innovative, yet risky, scientific platform.
Debt to book value of all companies in the market
Indaptus Therapeutics is developing a new approach to cancer immunotherapy. As with many early-stage biotechs, accessing funding for clinical trials is a matter of survival. This chart, reflecting the overall debt situation in the economy, helps us understand the environment in which Indaptus is raising capital to advance its innovative platform.
P/E of the company, segment and market as a whole
P/E - INDP
For Indaptus Therapeutics, an immuno-oncology company, the P/E ratio is not applicable. It has no profit, and its valuation on this chart is arbitrary. It's a speculative bet that its unique approach to "awakening" the immune system to fight cancer will be successful.
P/E of the market segment - Pharma immune
Indaptus Therapeutics is a biotech company developing a new approach to immunotherapy for cancer and viral infections. Their technology uses weakened bacteria to activate both innate and adaptive immunity. This chart shows the average valuation for the pharmaceutical sector, reflecting investor expectations for advanced immunotherapy platforms.
P/E of the market as a whole
Indaptus Therapeutics is developing a new generation of immunotherapy that uses bacteria to activate both the innate and adaptive immune systems to fight cancer. This unique approach is in its early stages. This risk appetite chart helps understand how investors evaluate high-risk but potentially breakthrough biotechnologies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company INDP
Indaptus Therapeutics is developing a new approach to immunotherapy for cancer and infectious diseases, using weakened bacteria to activate the immune system. This chart shows investor confidence in the potential of this unique technology. Future profits depend on the success of clinical trials and partnerships with pharmaceutical companies.
%20P%2FE%20INDP&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-INDP&v=1772544668969 "Chart of the company's future (projected) P/E INDP")
Future (projected) P/E of the market segment - Pharma immune
Indaptus Therapeutics is developing a platform for activating the immune system to fight cancer. This chart reflects the market's relative assessment of its scientific approach. It shows whether investors consider its technology more or less promising than other innovative immunotherapies in development by competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772544668974 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Indaptus Therapeutics is developing a universal immunotherapy for the treatment of cancer and infectious diseases by activating the innate immune system. The company's future depends on scientific breakthroughs and funding. This chart, reflecting market optimism, is an indicator of the investor appetite for risk required to support such innovative biotech platforms.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772544668992 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit INDP
Indaptus Therapeutics is an immuno-oncology company developing a novel cancer therapy. Its financial activity consists of expenses on preclinical and clinical trials. This chart illustrates the financial model of a biotech startup, where current expenses are invested in a potentially breakthrough treatment that could impact future revenues.
Profit of companies in the market segment - Pharma immune
Indaptus Therapeutics is developing novel anti-cancer and antiviral immunotherapies that activate both innate and adaptive immunity. This graph, showing overall sector profitability, reflects the potential of these versatile approaches. A breakthrough in Indaptus' research could lead to the creation of a platform for treating multiple diseases and fundamentally change the industry.
Overall market profit
Indaptus Therapeutics is developing a new approach to cancer treatment using bacteria to stimulate the immune system. This is a cutting-edge scientific concept that requires years of research. Investing in Indaptus is a bet on a scientific hypothesis, and its success will be determined in the clinic, not by the overall dynamics of market profits.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company INDP
Indaptus Therapeutics is developing a novel approach to immunotherapy for cancer and infectious diseases. The future revenue projections presented here are speculative. They reflect analyst expectations based on clinical trial results and the potential of its unique technology to activate the immune system against disease.
%20profit%20of%20the%20company%20INDP&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-INDP&v=1772544669044 "Graph of future (projected) profit of the company INDP")
Future (predicted) profit of companies in the market segment - Pharma immune
Indaptus Therapeutics is developing a versatile immunotherapy platform for the treatment of a wide range of oncological diseases. This chart shows future revenue expectations for the entire immunotherapy segment. It allows one to assess how the company's technology, which aims to activate the body's immune system, fits into the overall outlook for this cutting-edge field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772544669075 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Indaptus Therapeutics is developing a new approach to cancer immunotherapy. For a company whose technologies are still in preclinical and early clinical trials, this schedule is important for access to funding. The positive economic backdrop reflected here increases investor risk appetite and facilitates raising funds for continued research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772544669158 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - INDP
Indaptus Therapeutics is developing a new class of immunotherapeutic drugs for cancer treatment. For a biotech company whose technology is still in clinical trials, this metric is a measure of hope. It demonstrates a high valuation based not on current sales, but on investors' faith in the breakthrough potential of its versatile platform.
P/S market segment - Pharma immune
Indaptus Therapeutics is developing novel anti-cancer and anti-infective immunotherapies that use proprietary bacterial strains to activate the immune system. This chart reflects the premium investors are willing to pay for revenue in the advanced biotech sector, demonstrating the level of faith in Indaptus' innovative and broadly applicable approach.
P/S of the market as a whole
Indaptus Therapeutics is developing a new approach to immunotherapy for cancer and infectious diseases, using weakened bacteria to activate innate and adaptive immunity. This chart, showing the average revenue estimate, illustrates that investors value Indaptus based on the scientific potential of its platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company INDP
Indaptus Therapeutics is developing a new approach to cancer immunotherapy. For a company in the research stage, this chart is critically important: it shows how investors assess its potential future revenue from unreleased drugs. This trend reflects the market's confidence in the success of its technology and its ability to bring the drugs to market.
%20P%2FS%20INDP&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-INDP&v=1772544669446 "The graph of the company's future (projected) P/S INDP")
Future (projected) P/S of the market segment - Pharma immune
Indaptus Therapeutics is developing a new platform for activating the immune system to treat cancer and infectious diseases. The chart shows the average estimated future revenue in the immunology sector. It helps understand how the market views Indaptus's unique approach using killed bacteria and its potential compared to other immunotherapy strategies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772544669515 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Indaptus Therapeutics (INDP) is developing a new cancer immunotherapy platform. Their potential depends entirely on the success of clinical trials and scientific breakthroughs. This market forecast schedule has no bearing on their business, which is at the forefront of medical science and fights cancer.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772544669528 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales INDP
Indaptus Therapeutics is developing a novel approach to cancer immunotherapy. Being in the clinical stage, it does not generate revenue from drug sales. Its revenue comes from licensing agreements and partnerships. This chart reflects the financial revenues that validate the value of its technology and allow it to continue its cost-effective research.
Sales of companies in the market segment - Pharma immune
Indaptus Therapeutics is developing a new immunotherapy platform that activates both innate and adaptive immunity to fight cancer. Currently in the clinical stage, the company has no revenue yet. Its future revenue will depend on the success of this versatile technology in treating various tumor types.
Overall market sales
Indaptus Therapeutics is developing a new approach to cancer immunotherapy. Like many biotech companies, it is not dependent on consumer cycles. Its future is determined by scientific advances. However, the overall economic environment, shown in this chart, shapes the investment landscape, influencing investors' willingness to invest in high-risk scientific projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company INDP
Indaptus Therapeutics is a biotech company developing novel immunotherapies for the treatment of cancer. As its products are in early clinical trials, this chart represents a long-term analyst view of the scientific and commercial potential of its unique immune activation technology.
%20sales%20of%20the%20company%20INDP&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-INDP&v=1772544669658 "Schedule of future (projected) sales of the company INDP")
Future (projected) sales of companies in the market segment - Pharma immune
Indaptus Therapeutics is developing universal immunotherapies for the treatment of various cancers and infectious diseases by activating the innate immune system. This chart shows the outlook for the immunology pharmaceutical segment. It reflects the demand for new immunotherapy approaches, which is important for advancing Indaptus's unique platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772544669680 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Investment activity in the pharmaceutical industry, closely linked to the forecasts in this chart, determines the prospects for Indaptus Therapeutics. The biotech company, which develops immunotherapy, relies on funding for clinical trials. Positive economic expectations are driving capital inflows into risky projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772544669754 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality INDP
Indaptus Therapeutics is developing a new class of immunotherapeutic drugs for the treatment of cancer. This chart shows the company's financial status during the intensive research and development phase. Profitability is a long-term goal, dependent on the success of clinical trials and the validation of its unique anti-cancer platform.
Market segment marginality - Pharma immune
Indaptus Therapeutics is developing a new generation of immunotherapeutics that use bacteria to activate anti-tumor immunity. Profitability depends on the success of this innovative approach. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the potential and risks associated with Indaptus's unique technology platform.
Market marginality as a whole
Indaptus Therapeutics is developing a new immunotherapy approach for cancer treatment. The company's future depends on successful clinical trials and partnerships with major pharmaceutical companies. This chart shows the general investment environment. During periods of economic growth, investors and pharmaceutical giants are more inclined to invest in risky but innovative therapeutic platforms.
Employees in the company, segment and market as a whole
Number of employees in the company INDP
Indaptus Therapeutics is developing a new generation of immunotherapy for cancer treatment. This graph shows the size of the scientific and clinical team advancing their unique technology. A small and focused team is typical for early-stage biotech companies. Growth will indicate a transition to larger clinical trials and expanded R&D.
Share of the company's employees INDP within the market segment - Pharma immune
Indaptus Therapeutics is developing a novel immunotherapy platform that activates both innate and adaptive immunity to fight cancer and infections. This chart shows the company's share of all scientists in this cutting-edge field. This reflects its unique scientific approach and potential for creating universal immunotherapeutics.
Number of employees in the market segment - Pharma immune
Indaptus Therapeutics is developing innovative anti-cancer and antiviral immunotherapies using bacterial vectors to activate the immune system. This chart, showing employment in the immunopharmaceutical sector, is important. The growing number of researchers in this cutting-edge field speaks to the race to create versatile and powerful methods for activating immunity against disease.
Number of employees in the market as a whole
Indaptus Therapeutics is developing a new approach to activating the immune system to fight cancer. The success of such biotech companies depends on the availability of capital. This total employment graph reflects the health of the economy, which is essential for venture capital financing. Investors are more willing to invest in risky but promising projects during periods of economic stability.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company INDP (INDP)
Indaptus Therapeutics is another immuno-oncology company. They activate the immune system to fight cancer. This metric demonstrates that the company's market value is not tied to headcount in the traditional sense. The company's entire market capitalization is essentially a bet by investors on the success of their scientific platform and clinical trials.
%20of%20the%20company%20INDP%20(INDP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-INDP-INDP&v=1772544670098 "Chart of market capitalization per employee (in thousands of dollars) of the company INDP (INDP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Indaptus Therapeutics is developing a new class of anti-cancer and anti-infective immunotherapies. The company's value is derived almost entirely from its scientific developments and patent portfolio. This metric clearly illustrates that in biotech, market capitalization often relies on a very small but highly skilled team of scientists.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772544670194 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Indaptus Therapeutics is developing a new approach to immunotherapy, using bacteria to activate immune responses against cancer and infections. The company's market capitalization is based on its unique scientific platform. This chart shows a very high valuation per employee, as investors are betting on a breakthrough technology being developed by a small scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772544670263 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company INDP (INDP)
Indaptus Therapeutics is developing a new cancer immunotherapy platform using bacteria to stimulate the immune response. This is very early and speculative R&D. This graph shows the net investment (negative return) per researcher working on the proof of concept of this unconventional therapy, not the profit.
%20Chart%20INDP%20(INDP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-INDP-INDP&v=1772544670298 "Company Profit Per Employee (in thousands of dollars) Chart INDP (INDP)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Indaptus Therapeutics develops immunotherapeutic drugs. As with many biotechs in the research phase, this chart reflects the efficiency of investment capital rather than operating profit. Investors analyze this metric alongside clinical trial progress, as future revenue is directly dependent on their success.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772544670320 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Indaptus Therapeutics (INDP) is a biotech company developing novel bacterial-based immunotherapies for the treatment of cancer and viral diseases. It is a preclinical R&D company, and its entire staff consists of scientists. This indicator is negative, reflecting the high cost of investing in a single employee to create an innovative therapeutic platform.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772544670327 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee INDP (INDP)
Indaptus Therapeutics is developing a new cancer immunotherapy platform. As with many early-stage biotechs, this graph shows minimal or no revenue. Its true value will be revealed after successful clinical trials, when the team's intellectual capital is converted into sales.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-INDP-INDP&v=1772544670352 "Sales chart per company employee INDP (INDP)")
Sales per employee in the market segment - Pharma immune
Indaptus Therapeutics is a biotech company developing a platform for activating innate immunity to fight cancer. This is an early-stage, clinical-stage R&D company. The company has no revenue. This chart illustrates R&D personnel costs. The productivity of their scientific team is determined by patent creation and research progress, not current revenue.
Sales per employee for the market as a whole
Azenta (AZTA) provides solutions for the life sciences industry, specializing in sample management (cryostorage) and genomic services. This is critical infrastructure for pharmaceutical R&D. This chart reflects the effectiveness of their high-tech services. Automated storage systems (cryobanks) and high-throughput sequencing enable Azenta to process massive volumes of samples and data.
Short shares by company, segment and market as a whole
Shares shorted by company INDP (INDP)
Indaptus Therapeutics (INDP) is another biotech company working in cancer immunotherapy. This chart shows the volume of short positions. "Shorts" here are a classic bet that the company's science, no matter how promising, won't translate into a successful and safe drug.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-INDP-INDP&v=1772544670411 "Short Shares Chart for the Company INDP (INDP)")
Shares shorted by market segment - Pharma immune
Indaptus (INDP) is developing immunotherapy using bacteria to "awaken" the immune system against cancer. The chart below shows the aggregate short interest in the immuno-oncology sector. It shows how many investors are skeptical of new, unconventional approaches to cancer treatment.
Shares shorted by the overall market
Indaptus Therapeutics is developing a platform to activate the immune system against cancer. It's a complex and expensive biotech. This chart measures general fear. When investors are pessimistic, they're unwilling to take on the "binary" risk of clinical trials. They sell off INDP shares, fearing the company won't be able to raise capital to complete R&D in a market panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator INDP (INDP)
This chart for Indaptus is an indicator of faith in bacterial immunotherapy. The company uses weakened bacteria to "turn on" the immune system against cancer. "Overheating" (above 70) occurs with positive preclinical or early clinical data. This is a high-risk technology, and any concerns about safety or efficacy lead to an "oversold" position.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-INDP-INDP&v=1772544670516 "RSI 14 indicator chart for the company's stock INDP (INDP)")
RSI 14 Market Segment - Pharma immune
Indaptus Therapeutics is a biopharmaceutical company developing a unique immunotherapy. They use killed but immunologically active bacteria to "awaken" the immune system against cancer and viruses. This chart reflects the overall sentiment in the immuno-oncology sector. It helps assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
Indaptus Therapeutics (INDP) develops treatments for cancer and infections. For a biotech company in the development stage, investor sentiment is critical. This chart measures the "temperature" of the entire market. When the market is "overheated" (euphoria), investors generously fund risky projects. During periods of panic (oversold conditions), investors flee to "safe" assets, making it difficult for INDP to raise funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast INDP (INDP)
Indaptus Therapeutics is a biotech company developing a unique immunotherapy (Decoy) based on decellularized bacteria to activate the immune system against cancer. This chart shows the speculative average 12-month price target from analysts based on their belief in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-INDP-INDP&v=1772544670602 "A chart showing analyst consensus forecasts for the expected stock price. INDP (INDP)")
The difference between the consensus estimate and the actual stock price INDP (INDP)
Indaptus is a biotech company developing a unique therapy (Decoy-molecules) that "reboots" the immune system to fight cancer. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their faith in this complex yet innovative R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-INDP-INDP&v=1772544670623 "A chart showing the difference between the consensus forecast and the actual stock price. INDP (INDP)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Indaptus is an R&D biotech company developing bacterial-based immunotherapies to "awaken" the immune system against cancer. This is high-risk R&D. This chart reflects analysts' overall expectations for the entire immune pharma sector. It shows whether experts believe in this bacterial R&D platform.
Analysts' consensus forecast for the overall market share price
Indaptus Therapeutics is a biotech company developing a unique immunotherapy: they use (dead) bacteria to "awaken" the immune system to fight cancer. This chart shows the overall "risk appetite" in the market. For INDP, a clinical-stage company, overall market optimism (the rising chart) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index INDP
Indaptus is a bacterial biotech company. Their signature feature is non-living bacteria (Decoy), which (they claim) trains (activates) the innate immune system (NK cells) to attack cancer. This graph is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data and their chances of approval.
AKIMA Market Segment Index - Pharma immune
Indaptus Therapeutics uses a unique approach to cancer immunotherapy. They activate both innate and adaptive immunity to fight tumors, which may be more effective than existing methods. This chart compares their composite index to the sector, showing how their dual-targeted approach to cancer compares to their competitors.
The AKIM Index for the overall market
Indaptus Therapeutics is a biotech company developing Pulse-Prime technology to activate the immune system against cancer and viruses. This chart, which reflects the market average, provides a macro backdrop. It helps assess how INDP, a new approach to immunotherapy, compares to overall economic trends.
